Literature DB >> 20955263

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.

Anders Christensson1, Laila Bruun, Thomas Björk, Angel M Cronin, Andrew J Vickers, Caroline J Savage, Hans Lilja.   

Abstract

STUDY TYPE: Diagnostic (exploratory cohort). LEVEL OF EVIDENCE: 2b.
OBJECTIVE: To assess variation of total prostate-specific antigen (tPSA), free PSA (fPSA), percent fPSA, human glandular kallikrein 2 (hK2) and intact PSA measured three times within 2 weeks. Knowledge of the variation in an individual's PSA level is important for clinical decision-making. PATIENTS AND METHODS: Study participants were 149 patients referred for prostate biopsy, of which 97 had benign disease and 52 had prostate cancer. Three blood samples were drawn with a median of 4 h between first and second samples and 12 days between first and third samples. Variability was described by absolute differences, ratios and intra-individual coefficients of variation. Total PSA, fPSA, hK2 and intact PSA were measured in anticoagulated blood plasma.
RESULTS: At baseline, the median tPSA was 6.8 (interquartile range, 4.5-9.6) ng/mL. The intra-individual variation was low for all biomarkers, and lowest for tPSA. For 80% of participants, the ratio between first and second time points for tPSA was in the range 0.91-1.09 and the ratio for percent fPSA was in the range 0.89-1.15. Total coefficients of variation between time 1 and 2 for tPSA, fPSA, percent fPSA, hK2 and intact PSA were 4.0%, 6.6%, 6.0%, 9.2% and 9.5%, respectively. The measurements taken several days apart varied more than those taken on the same day, although the variation between both time points was not large.
CONCLUSIONS: The intra-individual variation for all the kallikrein-like markers studied was relatively small, especially for samples drawn the same day. Few cases are reclassified between the time points. This indicates the high short-term biological and technical reproducibility of the tests in clinical use.
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20955263      PMCID: PMC3572723          DOI: 10.1111/j.1464-410X.2010.09761.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  30 in total

Review 1.  Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice.

Authors:  György Sölétormos; Axel Semjonow; Paul E C Sibley; Rolf Lamerz; Per Hyltoft Petersen; Walter Albrecht; Peter Bialk; Massimo Gion; Frank Junker; Hans-Peter Schmid; Hein Van Poppel
Journal:  Clin Chem       Date:  2005-06-16       Impact factor: 8.327

2.  Intraindividual variation in total and percent free prostate-specific antigen levels in prostate cancer suspects.

Authors:  Minoru Kobayashi; Shinsuke Kurokawa; Akihiko Tokue
Journal:  Urol Int       Date:  2005       Impact factor: 2.089

Review 3.  Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.

Authors:  D L Woodrum; M K Brawer; A W Partin; W J Catalona; P C Southwick
Journal:  J Urol       Date:  1998-01       Impact factor: 7.450

4.  Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.

Authors:  David Ulmert; Charlotte Becker; Jan-Ake Nilsson; Timo Piironen; Thomas Björk; Jonas Hugosson; Göran Berglund; Hans Lilja
Journal:  Clin Chem       Date:  2005-12-29       Impact factor: 8.327

5.  Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum.

Authors:  K Mitrunen; K Pettersson; T Piironen; T Björk; H Lilja; T Lövgren
Journal:  Clin Chem       Date:  1995-08       Impact factor: 8.327

Review 6.  Analysis of variation in prostate-specific antigen values.

Authors:  M Riehmann; P R Rhodes; T D Cook; G S Grose; R C Bruskewitz
Journal:  Urology       Date:  1993-10       Impact factor: 2.649

7.  Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population.

Authors:  C G Roehrborn; G J Pickens; T Carmody
Journal:  Urology       Date:  1996-01       Impact factor: 2.649

8.  Ejaculation increases the serum prostate-specific antigen concentration.

Authors:  M B Tchetgen; J T Song; M Strawderman; S J Jacobsen; J E Oesterling
Journal:  Urology       Date:  1996-04       Impact factor: 2.649

9.  Increase in percent free prostate-specific antigen in men with chronic kidney disease.

Authors:  Laila Bruun; Caroline Savage; Angel M Cronin; Jonas Hugosson; Hans Lilja; Anders Christensson
Journal:  Nephrol Dial Transplant       Date:  2008-11-21       Impact factor: 5.992

10.  Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers.

Authors:  A F Prestigiacomo; T A Stamey
Journal:  J Urol       Date:  1996-06       Impact factor: 7.450

View more
  4 in total

Review 1.  Screening for prostate cancer: early detection or overdetection?

Authors:  Andrew J Vickers; Monique J Roobol; Hans Lilja
Journal:  Annu Rev Med       Date:  2011-11-03       Impact factor: 13.739

2.  Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.

Authors:  David Ulmert; Andrew J Vickers; Howard I Scher; Charlotte Becker; Peter Iversen; David Frankel; Jens-Kristian Jensen; Tine Kold Olesen; Hans Lilja
Journal:  Clin Chem Lab Med       Date:  2012-11       Impact factor: 3.694

3.  Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer.

Authors:  Sanoj Punnen; Nicola Pavan; Dipen J Parekh
Journal:  Rev Urol       Date:  2015

4.  Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer.

Authors:  Donna Pauler Ankerst; Jonathan Gelfond; Martin Goros; Jesus Herrera; Andreas Strobl; Ian M Thompson; Javier Hernandez; Robin J Leach
Journal:  J Urol       Date:  2016-03-12       Impact factor: 7.450

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.